- |||||||||| dronabinol oral / Generic mfg.
Trial completion date, Trial primary completion date: Dronabinol in Total Knee Arthroplasty (TKA) (clinicaltrials.gov) - Jul 15, 2022
P4, N=110, Recruiting,
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- |||||||||| Sativex (nabiximols) / Jazz, JZP-150 / Jazz, Cesamet (nabilone) / Bausch Health, Viatris
Review: Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials. (Pubmed Central) - Jul 12, 2022
In contrast, modulators of endocannabinoid activity, i.e., nabiximols, cannabidiol and PF-04457845, demonstrated broader efficacy which covered almost all aspects of CUD. Endocannabinoid modulation appears to be a promising treatment approach in CUD, but the evidence to support this strategy is still small and future research in this direction is needed.
- |||||||||| dronabinol oral / Generic mfg.
Enrollment open, Surgery: Dronabinol After Arthroscopic Surgery (clinicaltrials.gov) - Jul 5, 2022
P3, N=30, Recruiting,
Endocannabinoid modulation appears to be a promising treatment approach in CUD, but the evidence to support this strategy is still small and future research in this direction is needed. Not yet recruiting --> Recruiting
- |||||||||| dronabinol oral / Generic mfg.
Trial completion: Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors (clinicaltrials.gov) - Jun 2, 2022
P2/3, N=50, Completed,
There is a lack of evidence pertaining to the benefits of cannabis in an aged population, and thus, additional research is warranted to support its use in the aged population. Active, not recruiting --> Completed
- |||||||||| dronabinol oral / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Tetrahydrocannabinol (THC) and Sleep (clinicaltrials.gov) - May 31, 2022
P1, N=18, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Sep 2021
- |||||||||| Procedural Sedation: Moving Beyond Opioids and Benzodiazepines () - May 30, 2022 - Abstract #SIR2022SIR_1971;
The combination of midazolam and fentanyl reliably provides anxiolysis, amnesia, analgesia, and sedation with the ability to rapidly reverse respiratory drive suppression, if necessary...Dexmedetomidine is a widely utilized medication in the neurological critical care setting.(1) However, its use is being studied in other settings due to the anxiolysis and sedation it provides without associated respiratory depression...However, the roles of these medications continue to expand with further study. Adjunctive pain management with ketamine infusion, lidocaine infusion, or dronabinol should be considered in patients undergoing procedures with significant post-procedural pain.
- |||||||||| Cesamet (nabilone) / Bausch Health, Viatris
Journal: Efficacy of cannabis and its constituents in disease management: Insights from clinical studies. (Pubmed Central) - May 29, 2022
The cannabis constituents have also been used in combination with other agents such as megestrol acetate in some clinical trials...This article provides a compilation of published studies focusing on clinal trials on the therapeutic effects of cannabis. The adverse effects of cannabis and its constituents are also discussed.
- |||||||||| dronabinol oral / Generic mfg.
Trends in Medicare Spending on Antiemetics (E-Poster Stage 1, Metropolitan Centre, CC) - May 22, 2022 - Abstract #MASCCISOO2022MASCC_ISOO_244;
For NKRAs and cannabinoids, generic (dronabinol, aprepitant) spending was negatively correlated with brand-name spending...The median CAGR for NKRAs and cannabinoids outpaced CPI and inflation. These findings offer insight into drug pricing and contributors to the high costs of antiemetics.
- |||||||||| morphine sulphate / Generic mfg., dronabinol oral / Generic mfg.
Preclinical, Retrospective data, Review, Journal: Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. (Pubmed Central) - May 22, 2022
Meta-analyses of observational studies found 39% reported opioid cessation (95% CI 0.15, 0.64, I 95.5%, eight studies), and 85% reported reduction (95% CI 0.64, 0.99, I 92.8%, seven studies). In summary, preclinical and observational studies demonstrate the potential opioid-sparing effects of cannabinoids in the context of analgesia, in contrast to higher-quality RCTs that did not provide evidence of opioid-sparing effects.
- |||||||||| The Implication of Nonpsychiatric Medications in Serotonin Syndrome () - May 5, 2022 - Abstract #APA2022APA_1089;
S’s medications revealed that he was taking home medications of duloxetine 60 mg, lurasidone 40 mg, and controlled release morphine 60 mg, and medications started in the hospital of ondansetron, prochlorperazine, dronabinol, antibiotics, oxycodone, and famotidine...There have been other case reports of serotonin syndrome secondary to cyclobenzaprine in the literature. 2,3,4 It is critical to look beyond psychiatric medications when considering serotonin syndrome.
- |||||||||| dronabinol oral / Generic mfg.
Efficacy of Medical Marijuana in the Treatment of Psychiatric Disorders - the Current State of the Evidence () - May 5, 2022 - Abstract #APA2022APA_455;
Results There are a number of open-label studies using dronabinol, and cannabis in the treatment of PTSD which showed promising improvement in symptom severity and insomnia...Adequately powered, high-quality studies that control for expectancy response are warranted. Physicians need to continue to exercise caution and discuss the risks vs benefits with patients seeking medical marijuana for psychiatric conditions.
- |||||||||| dronabinol oral / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Effects of THC and Alcohol on Driving Performance (clinicaltrials.gov) - Apr 25, 2022
P4, N=0, Withdrawn,
CBD treatment-by-gene interactions suggest potential benefit for postprandial distress with CNR1 rs806378 T allele. N=135 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2021 --> Dec 2021
- |||||||||| Sativex (nabiximols) / Jazz, Cesamet (nabilone) / Bausch Health, Viatris
Review, Journal: Cannabinoids: Therapeutic Use in Clinical Practice. (Pubmed Central) - Apr 9, 2022
Dronabinol was approved for the treatment of anorexia in patients with AIDS (acquired immune deficiency syndrome). In this review, we highlighted the potential therapeutic efficacy of natural and synthetic cannabinoids and their clinical relevance in cancer, neurodegenerative and dermatological diseases, and viral infections.
- |||||||||| dexamethasone / Generic mfg., mirtazapine / Generic mfg., dronabinol oral / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, HEOR: Nutrition and Pharmacological Algorithm for Oncology Patients Study (clinicaltrials.gov) - Apr 4, 2022
P4, N=1, Terminated,
N=30 --> 1 | Trial completion date: Dec 2021 --> Apr 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Apr 2021; The trial was closed after 4 months due to slow to accrual. Only 1 participant was enrolled.
- |||||||||| dronabinol oral / Generic mfg.
Review, Journal: Medical Cannabis in Pediatric Oncology: Friend or Foe? (Pubmed Central) - Mar 27, 2022
Additionally, promising preclinical evidence showing that cannabis has anti-cancer effects on pediatric cancer warrants further investigation of cannabis' use in pediatric cancer patients, as well as other populations of pediatric patients. This review aims to examine the evidence regarding the potential clinical utility of cannabis as an anti-cancer treatment in children by summarizing what is currently known about uses of medical cannabis in children, particularly regarding its anti-cancer potential.
- |||||||||| Review, Journal: Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. (Pubmed Central) - Mar 18, 2022
Management of neuropathic pain presents an unmet clinical need, with less than 50% of patients achieving substantial pain relief with medications currently recommended such as pregabalin, gabapentin, duloxetine and various tricyclic antidepressants...CbMs/MC are available in different forms: licensed medications or medical products (plant-derived and/or synthetic products such as tetrahydrocannabinol or cannabidiol); magistral preparations of cannabis plant derivatives with defined molecular content such as dronabinol (tetrahydrocannabinol); and herbal cannabis with a defined content of tetrahydrocannabinol and/or cannabidiol, together with other active ingredients (phytocannabinoids other than cannabidiol/tetrahydrocannabinol, terpenes and flavonoids)...Recommendations for the use of CbMs/MC for chronic neuropathic pain by various medical associations also differ, from negative recommendations, no recommendation possible, recommended as third-line therapy, or recommended as an alternative in selected cases failing standard therapies within a multimodal concept. After reading this paper, readers are invited to formulate their own conclusions regarding the potential benefits and harms of CbMs/MC for the treatment of chronic neuropathic pain.
- |||||||||| dronabinol oral / Generic mfg.
Review, Journal: Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review. (Pubmed Central) - Mar 16, 2022
A narrative summary of the findings from the limited number of studies in the area highlights an apparent association between cannabidiol-based products and relief from motor symptoms in HD and PD and an apparent association between synthetic cannabinoids and relief from behavioral and psychological symptoms of dementia across AD, PD, and HD. These preliminary conclusions could guide using plant-based versus synthetic cannabinoids as safe, alternative treatments for managing neuropsychiatric symptoms in neurocognitive vulnerable patient populations.
- |||||||||| Sativex (nabiximols) / Jazz, Lu AG06466 / Lundbeck
Clinical, Journal: Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. (Pubmed Central) - Mar 4, 2022
P3
Increasing evidence suggests that CBM is efficacious in the treatment of tics and psychiatric comorbidities in patients with GTS. The results of ongoing larger RCTs, such as CANNA-TICS (ClinicalTrials.gov Identifier: NCT03087201), will further clarify the role of CBM in the treatment of patients with GTS.
- |||||||||| dronabinol oral / Generic mfg.
Journal: Acute coronary syndrome associated with dronabinol (Pubmed Central) - Mar 3, 2022
The results of ongoing larger RCTs, such as CANNA-TICS (ClinicalTrials.gov Identifier: NCT03087201), will further clarify the role of CBM in the treatment of patients with GTS. No abstract available
- |||||||||| dronabinol oral / Generic mfg.
Assessing Nursing Knowledge, Attitude, and Current Practices on Medical Cannabinoids (Anaheim Convention Center - Learning Hall: Poster Pavilion) - Feb 25, 2022 - Abstract #ONS2022ONS_285;
At our current academic healthcare, there are no policies in place that allow the use of medical cannabis within the hospital setting, excluding use of low dose marinol...Recent discoveries on the endocannabinoid system have helped support the expansion of research on therapeutic properties of cannabinoids. Nursing staff need to remain current on these new ways to support the oncology community and stay up to date on the latest scientific research within this topic on medical cannabinoid use.
- |||||||||| dronabinol oral / Generic mfg.
Review, Journal: Cannabinoids for the Treatment of Dermatologic Conditions. (Pubmed Central) - Feb 25, 2022
Dronabinol showed efficacy for trichotillomania...Available evidence suggests that CBs may be effective for the treatment of various inflammatory skin disorders. Although promising, additional research is necessary to evaluate efficacy and to determine dosing, safety, and long-term treatment guidelines.
- |||||||||| dronabinol oral / Generic mfg.
Preclinical, Journal: Dronabinol inhibits alveolar bone remodeling in tooth movement of rats. (Pubmed Central) - Feb 23, 2022
Although promising, additional research is necessary to evaluate efficacy and to determine dosing, safety, and long-term treatment guidelines. These results demonstrate that dronabinol attenuates orthodontic tooth movement by decreasing bone resorption, which could have implications for other bone-related recovery processes.
- |||||||||| Journal: Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. (Pubmed Central) - Feb 22, 2022
For diarrhea, the cost of generic loperamide or diphenoxylate-atropine tablets was <$15 USD...For cancer-associated fatigue, the cost of generic dexamethasone or dexmethylphenidate was <$15 USD, whereas brand-name modafinil was more costly ($1,284 USD)...We highlight the high costs of many symptom control drugs and the wide variation in the costs of these drugs. These findings can guide patient-clinician discussions about cost-effectively managing symptoms, while promoting the use of less expensive formulations when possible.
|
